close

Clinical Trials

Date: 2011-11-24

Type of information: Results

phase: preclinical

Announcement: results

Company: Genfit (France)

Product: GFT505

Action mechanism: PPAR agonist. Elafibranor (GFT505) is an oral once-daily treatment, and a first-in-class drug acting via dual peroxisome proliferator-activated alpha/delta pathways to treat nonalcoholic steatohepatitis (NASH).

Disease: NASH (non-alcoholic steatohepatitis)/NAFLD (non-alcoholic fatty liver disease)

Therapeutic area: Liver diseases - Metabolic diseases

Country:

Trial details:

Latest news:

Genfit has announced new pre-clinical data showing that the administration of GFT505 blocks pro-fibrotic mechanisms and leads to the complete regression of the hepatic steatosis associated with NAFLD/NASH. After having demonstrated the clinical efficacy of GFT505 on numerous markers associated with NAFLD/NASH in pre-diabetic and diabetic patients, Genfit is preparing to launch a major international study in this indication. In this context, two new series of pre-clinical studies show the therapeutic efficacy of GFT505 on established hepatic disorders: - After having induced NAFLD/NASH by feeding a diet deficient in methionine and choline (MCDD) for 4 weeks to diabetic animals, GFT505 or vehicle control were administered at the same time as the MCDD for a further 4 weeks. The macroscopic examination of the liver after treatment demonstrates that GFT505 completely eliminates the steatosis induced by the MCDD, while this finding persists in the vehicle group. In parallel, hepatic dysfunction markers are completely normalized in the GFT505-treated group. - After having induced major hepatic fibrosis in animals by the injection of a pro-fibrotic chemical agent (carbon tetrachloride, CCl4) for 2 weeks, GFT505 or vehicle control were administered at the same time as CCl4 for a further 4 weeks. The microscopic examination of the liver demonstrates that GFT505 completely blocks the development of fibrosis, whereas this continues to worsen in the control group. These results open the possibility of evaluating the potential of GFT505 in other diseases associated with hepatic fibrosis, such as primary biliary cirrhosis, viral hepatitis, or drug-induced hepatitis .

Is general: Yes